Q1 Earnings Estimate for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at B. Riley issued their Q1 2025 earnings estimates for shares of TG Therapeutics in a research note issued to investors on Tuesday, March 4th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will post earnings of $0.21 per share for the quarter. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.73 EPS.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million.

A number of other brokerages have also weighed in on TGTX. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday. Finally, StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Price Performance

TGTX stock opened at $38.44 on Thursday. TG Therapeutics has a 12 month low of $12.93 and a 12 month high of $38.58. The company has a 50-day moving average price of $30.95 and a 200 day moving average price of $28.43. The stock has a market cap of $5.98 billion, a PE ratio of -384.36 and a beta of 2.30. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after purchasing an additional 209,190 shares in the last quarter. State Street Corp raised its holdings in shares of TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock valued at $212,712,000 after purchasing an additional 2,398,015 shares in the last quarter. Soleus Capital Management L.P. raised its holdings in shares of TG Therapeutics by 5.8% in the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after purchasing an additional 146,702 shares in the last quarter. Clearbridge Investments LLC bought a new stake in shares of TG Therapeutics in the 4th quarter valued at about $55,237,000. Finally, Northern Trust Corp raised its stake in shares of TG Therapeutics by 8.6% during the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after acquiring an additional 120,785 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

Insider Activity

In other news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.